If approved by the EC, Tagrisso will be the first targeted therapy for European patients with unresectable EGFR-mutated cancer.

The CHMP renders a positive opinion recommending approval for MRK's Keytruda for the first-line treatment of malignant ...

The European Union health agency on Monday warned that Europe was set to miss goals on reducing the use of antibiotics, ...

That Thursday, for the first time, the European Medicines Agency (EMA) approved a drug that targets the cause — not just the ...

NORTH CHICAGO, IL, USA I 18, 2024 I AbbVie (NYSE: ABBV) today announced the European Commission (EC) granted marketing authorization for ELAHERE® ...

The New Drug Application is based on positive results from the Phase 3 PALISADE study – People living with familial chylomicronemia syndrome have extremely high triglyceride ...

Amidst a backdrop of global economic downturn and increasingly cautious investment trends in the pharmaceutical sector, this ...

Lecanemab, a drug designed to slow the progression of early stage Alzheimer's will not be available to patients in Sweden for ...

The study showed significant reductions in serum TTR levels in subjects after a single dose, with sustained effects over time ...

These bacteria have evolved the ability to resist treatment with antibiotics, and it's making them more deadly and harder to ...

Moberg Pharma's MOB-015 has outstanding clinical trial data, 76% cure rate, double the current standard topical, Jublia. Read ...

Princeton: Bristol Myers Squibb has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European ...